×

Browse

ESMO 2021 Jazz Pharmaceuticals AML symposium

Insight beyond Phase 3: Does real-world evidence impact how we treat high-risk AML

High-risk AML defined as therapy-related AML (t-AML) or AML with myelodysplasia related changes (AML-MRC).

Chair: Prof Hartmut Döhner

This is a promotional symposium for healthcare professionals only.

Prescribing information and adverse event reporting details will be available during the sessions of the symposium